Roundup

Five things for pharma marketers to know: Friday, June 9, 2023

Jack O'Brien

June 9, 2023

5:00 am

Upstream Bio raises another $200 million to get through Phase II studies; Samsung Biologics signs $411 million deal with Pfizer to manufacture the drugmaker’s biosimilars portfolio; Pope Francis is in “good general condition” following a three-hour abdominal surgery.

Five things for pharma marketers to know: Thursday, June 8, 2023

Jack O'Brien

June 8, 2023

5:00 am

New York City air quality suffers from Canadian wildfires; The FDA signals that Leqembi is up for a likely full approval next month; Military officials say the quality of generic drugs is concerning, DoD devising a program to test the safety of widely used medicines.

Five things for pharma marketers to know: Wednesday, June 7, 2023

Lecia Bushak

June 7, 2023

5:00 am

Merck sues federal government over Medicare drug pricing negotiations; Sanofi and AstraZeneca’s experimental preventive RSV therapy appears to be safe, FDA says; The Apple Watch will track users’ mental health statuses.

Five things for pharma marketers to know: Tuesday, June 6, 2023

Lecia Bushak

June 6, 2023

5:00 am

Elon Musk’s Neuralink is reportedly worth around $5 billion; Biogen cuts Phase 3 Parkinson’s trial for BIIB122 as part of R&D restructuring; White House considers Mandy Cohen as CDC Director Rochelle Walensky’s successor.

Five things for pharma marketers to know: Monday, June 5, 2023

Jack O'Brien

June 5, 2023

5:00 am

Novartis’s breast cancer drug Kisqalt reduces the risk of tumors returning by 25%; BioNTech says a cancer immunotherapy candidate it is working on with OncoC4 shrunk tumors in close to 30% of participants in a mid-stage lung cancer trial; Mark Cuban’s Cost Plus Drugs Company is set to compete with AbbVie’s Humira franchise.

Five things for pharma marketers to know: Friday, June 2, 2023

Jack O'Brien

June 2, 2023

5:00 am

CMS plans to broadly cover a new class of Alzheimer’s drugs pending approval by the FDA; Sandoz is set to move to a new central Basel headquarters by mid-2024; Eikon Therapeutics announced three business development deals and more than $100 million in fresh funding.

Five things for pharma marketers to know: Thursday, June 1, 2023

Lecia Bushak

June 1, 2023

5:00 am

RA Capital-backed Summation Bio is “terminating operations” next month; Abbott sues former scientist over alleged trade-secret theft; FDA puts clinical hold on PepGen’s myotonic dystrophy type 1 drug.

Five things for pharma marketers to know: Wednesday, May 31, 2023

Jack O'Brien

May 31, 2023

5:00 am

Atea Pharmaceuticals rejects Tang Capital’s unsolicited takeover bid; Eli Lilly partners with AI-powered drug discoverer Xtalpi in a deal worth up to $250 million; Movement suggests the body, rather than the mind, is the origin of our feelings.

Five things for pharma marketers to know: Tuesday, May 30, 2023

Jack O'Brien

May 30, 2023

5:00 am

Moderna says it is looking for opportunities in China after confirming that it registered a legal entity there; Walgreens cuts 10% of its corporate workforce; The government’s waiting period for Merck’s $10.8 billion Prometheus Biosciences buyout expired.

Five things for pharma marketers to know: Friday, May 26, 2023

Lecia Bushak

May 26, 2023

5:00 am

FDA grants full approval to Pfizer’s COVID-19 pill Paxlovid; Illumina shareholders oust board chairman John Thompson; Noom launches an option that will include prescriptions for obesity drugs like Wegovy.

Five things for pharma marketers to know: Thursday, May 25, 2023

Lecia Bushak

May 25, 2023

5:00 am

FDA delays decision on Sarepta’s Duchenne muscular dystrophy gene therapy by one month; Brain and spine implants allows a paralyzed man to walk naturally again; Eloxx Pharmaceuticals plans to move its lead candidate into a Phase 3 clinical trial.

Five things for pharma marketers to know: Wednesday, May 24, 2023

Lecia Bushak

May 24, 2023

5:00 am

How Republican presidential candidate and former Roivant Sciences CEO Vivek Ramaswamy turned Martin Shkreli into the ‘Pharma Bro’; The FDA approves a new easy-to-use version of a medication to reverse overdoses caused by fentanyl; Ironwood bulks up on its digestive therapies with a $1.15 billion purchase of VectivBio.

Five things for pharma marketers to know: Tuesday, May 23, 2023

Jack O'Brien

May 23, 2023

5:00 am

Pfizer’s oral weight loss drug may be as effective as and quicker than Ozempic injection by Novo Nordisk; Prelude Therapeutics, Cabaletta Bio raise around $161 million combined in public stock sales; Novartis bolstered its gene therapy pipeline by spending $87.5 million on an Avrobio therapy.

Five things for pharma marketers to know: Monday, May 22, 2023

Jack O'Brien

May 22, 2023

5:00 am

Novartis drops some early-stage cancer drugs from its pipeline; FDA clears Thermo Fisher Scientific’s test to detect women with risk of severe preeclampsia; Moderna presents promising early data on its mRNA treatment for propionic acidemia.

Five things for pharma marketers to know: Friday, May 19, 2023

Jack O'Brien

May 19, 2023

5:00 am

Eli Lilly’s treatment for rheumatoid arthritis meets main goal for efficacy; Eyepoint Pharmaceuticals sells Yutiq to Alimera Sciences for $82.5 million; A Midwest anti-abortion group uses cellphone location data to target online content to visitors of certain Planned Parenthood clinics.